Trelegy Ellipta is a once-daily triple-combination inhaler for COPD and asthma, and its closest comparable option is Breztri Aerosphere, the only other single-inhaler triple therapy approved in the United States. Beyond that direct substitute, several dual-combination inhalers can serve as alternatives depending on your symptoms and exacerbation history. Which option fits best depends on how severe your condition is, whether you need a steroid component, and what your insurance covers.
Breztri Aerosphere: The Closest Match
Breztri Aerosphere is the most direct alternative to Trelegy because it contains the same three classes of medication in a single device: an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-agonist. The specific active ingredients differ (budesonide, glycopyrrolate, and formoterol in Breztri versus fluticasone furoate, umeclidinium, and vilanterol in Trelegy), but the therapeutic approach is identical. Both are approved for maintenance treatment of COPD in people who have frequent or severe flare-ups.
The biggest practical difference is dosing. Trelegy is a dry-powder inhaler used once a day. Breztri is a metered-dose inhaler used twice a day. For some people, once-daily dosing is simpler and easier to stick with. Others prefer a metered-dose inhaler because the technique feels more familiar or because the device is easier to use with weaker inspiratory effort. No head-to-head randomized trial has directly compared the two, so there is no definitive evidence that one works better than the other.
How the Two Triple Therapies Compare on Cost
At list price, Trelegy and Breztri are nearly identical. The 2024 wholesale acquisition cost is about $643 per 30-day supply for Trelegy and $645 for Breztri. What you actually pay, though, depends heavily on your insurance plan and available manufacturer rebates.
Based on 2023 claims data from Oregon’s drug pricing review, the average out-of-pocket cost per fill was $55 for Trelegy and $71 for Breztri in commercial insurance plans. After rebates and other discounts, insurers paid roughly $702 per Trelegy claim and $641 per Breztri claim. These numbers shift from plan to plan, so checking your formulary is the most reliable way to compare your personal costs. Both manufacturers offer copay cards and patient assistance programs that can bring costs down further.
Dual-Combination Inhalers as Step-Down Options
Not everyone needs all three medication classes. If your COPD is less severe, or if you haven’t had frequent exacerbations in the past year, a dual-combination inhaler may be a reasonable alternative. These pair two of the three drug types found in Trelegy, dropping the component you’re least likely to benefit from.
LAMA/LABA Combinations (No Steroid)
Inhalers like Anoro Ellipta combine a long-acting muscarinic antagonist with a long-acting beta-agonist but leave out the inhaled corticosteroid. This matters because the steroid component is the piece most responsible for reducing inflammatory flare-ups, but it also carries a higher risk of pneumonia. In the large IMPACT trial, which followed more than 10,000 people with moderate to very severe COPD, Trelegy reduced the annual rate of moderate or severe exacerbations by about 25% compared with Anoro and lowered COPD-related hospitalizations by roughly one-third. Pneumonia, however, was more common with Trelegy.
A steroid-free dual inhaler may be a better fit if you have COPD without an asthma component, you’ve had few or no recent exacerbations, you have a history of pneumonia, or you and your prescriber want to minimize steroid exposure. It also tends to cost less, which can matter if you’re paying a significant portion out of pocket.
ICS/LABA Combinations (No Muscarinic Antagonist)
Inhalers like Breo Ellipta or Symbicort pair an inhaled corticosteroid with a long-acting beta-agonist. These are commonly used for asthma and can also be prescribed for COPD. They keep the anti-inflammatory benefit of the steroid but lack the additional bronchodilation from a muscarinic antagonist. For people whose breathing limitation responds well to just two agents, this combination can be sufficient.
Using Two Separate Inhalers Together
Before single-device triple therapies existed, the standard way to get all three drug classes was to use two inhalers: one containing a corticosteroid plus a long-acting beta-agonist, and a separate long-acting muscarinic antagonist inhaler like Spiriva. This approach delivers the same medication classes as Trelegy, just split across two devices. Some insurance plans still prefer this route because the individual components may be available as generics or at lower formulary tiers. The tradeoff is complexity. Carrying two devices, each with its own dosing schedule and inhalation technique, increases the chance of missed doses or incorrect use.
Trelegy’s Two Strengths
Trelegy comes in two dose levels: 100/62.5/25 and 200/62.5/25, measured in micrograms. The difference is entirely in the corticosteroid dose (100 versus 200 mcg of fluticasone furoate). The lower strength is approved for COPD, while the higher strength is typically used for asthma. If you’re looking for a comparable option because of side effects from the steroid component, switching to the lower-dose version of Trelegy itself (rather than a different product) may be worth discussing.
No Generic Trelegy Yet
The FDA has not approved a generic version of Trelegy Ellipta. Multiple patents protect the product through at least late 2030, with some extending into 2031. Until those patents expire and generic manufacturers receive approval, Breztri remains the only branded single-inhaler alternative delivering all three drug classes. If cost is the primary reason you’re looking for a comparable option, manufacturer savings programs, patient assistance through the drugmaker, or switching to a dual-therapy inhaler that lands on a lower formulary tier are the most practical paths right now.
Choosing the Right Alternative
The best comparable option depends on why you’re looking for one. If you want the same triple-therapy approach in a single device, Breztri Aerosphere is the only direct substitute. If you’re open to dropping the steroid, a LAMA/LABA combination like Anoro can simplify your regimen and lower pneumonia risk, though it won’t suppress exacerbations as effectively in high-risk patients. If cost is the driving factor, combining two separate inhalers or checking whether Breztri sits on a better tier in your plan are both worth exploring. Current guidelines from the Global Initiative for Chronic Obstructive Lung Disease recommend triple therapy specifically for people with frequent or severe exacerbations and elevated blood eosinophil counts, so the level of therapy you actually need is the first question to settle.